Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 204840, 13 pages
http://dx.doi.org/10.1155/2014/204840
Review Article

Protective Effects of Panax Notoginseng Saponins on Cardiovascular Diseases: A Comprehensive Overview of Experimental Studies

1Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
2Cancer Research Institute, Central South University, Changsha, Hunan 410078, China

Received 27 November 2013; Accepted 28 May 2014; Published 24 July 2014

Academic Editor: Arthur Sá Ferreira

Copyright © 2014 Xiaochen Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Chan, G. N. Thomas, and B. Tomlinson, “Protective effects of trilinolein extracted from Panax notoginseng against cardiovascular disease,” Acta Pharmacologica Sinica, vol. 23, no. 12, pp. 1157–1162, 2002. View at Google Scholar · View at Scopus
  2. T. T. X. Dong, X. M. Cui, Z. H. Song et al., “Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents,” Journal of Agricultural and Food Chemistry, vol. 51, no. 16, pp. 4617–4623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Yao, W. Y. Wu, S. H. Guan et al., “Proteomic analysis of differential protein expression in rat platelets treated with notoginsengnosides,” Phytomedicine, vol. 15, no. 10, pp. 800–807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Ying, “Pharmacodynamical research and clinical application of Panax pseudo-ginseng saponins,” Guangxi Medical Journal, vol. 20, no. 6, pp. 1109–1112, 1998. View at Google Scholar
  5. L.-M. Yu, Y.-K. Deng, F. Yuan et al., “The research progress of Panax notoginseng saponins against myocardial ischemia,” China Pharmacist, vol. 14, no. 11, pp. 1685–1687, 2011. View at Google Scholar
  6. L. W. T. Cheung, K. W. Leung, C. K. C. Wong, R. N. S. Wong, and A. S. T. Wong, “Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fibroblast growth factor receptor-1,” Cardiovascular Research, vol. 89, no. 2, pp. 419–425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. W. Leung, H. M. Ng, M. K. S. Tang, C. C. K. Wong, R. N. S. Wong, and A. S. T. Wong, “Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1α to promote angiogenesis,” Angiogenesis, vol. 14, no. 4, pp. 515–522, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. Z.-T. Wang, L.-H. Han, M.-J. Zhu et al., “Effects of Chinese traditional medicines on angiogenesis and correlative growth factor expression in the ischemic myocardium of the rats with myocardial infarction,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 4, no. 4, pp. 305–307, 2006. View at Google Scholar
  9. The Collaborative Study Group on Trends of Cardiovascular Diseases in China and Prevention, “Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades,” Chinese Journal of Cardiology, vol. 29, pp. 74–79, 2001. View at Google Scholar
  10. C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth, “Platelet-active drugs: the relationships among dose, effectiveness, and side effects,” Chest, vol. 126, no. 3, supplement, pp. 234S–264S, 2004. View at Google Scholar · View at Scopus
  11. A. J. Lau, D. F. Toh, T. K. Chua, Y. K. Pang, S. O. Woo, and H. L. Koh, “Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium,” Journal of Ethnopharmacology, vol. 125, no. 3, pp. 380–386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Zhang, J. Wojta, and B. R. Binder, “Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery,” Cellular and Molecular Biology, vol. 43, no. 4, pp. 581–587, 1997. View at Google Scholar · View at Scopus
  13. S. Chen, J. Liu, X. Liu et al., “Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 263–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Palojoki, A. Saraste, A. Eriksson et al., “Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 280, no. 6, pp. H2726–H2731, 2001. View at Google Scholar · View at Scopus
  15. A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, and L. Voipio-Pulkki, “Apoptosis in human acute myocardial infarction,” Circulation, vol. 95, no. 2, pp. 320–323, 1997. View at Google Scholar · View at Scopus
  16. F. J. Giordano, “Oxygen, oxidative stress, hypoxia, and heart failure,” Journal of Clinical Investigation, vol. 115, no. 3, pp. 500–508, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Q. Zhao, J. S. Corvera, M. E. Halkos et al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579–H588, 2003. View at Google Scholar
  18. H. Kin, Z. Q. Zhao, H. Y. Sun et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion,” Cardiovascular Research, vol. 62, no. 1, pp. 74–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fujita, H. Asanuma, A. Hirata et al., “Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 4, pp. H2004–H2008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Crompton, S. Virji, V. Doyle, N. Johnson, and J. M. Ward, “The mitochondrial permeability transition pore,” Biochemical Society Symposium, vol. 66, pp. 167–179, 1999. View at Google Scholar · View at Scopus
  21. S. M. Davidson, D. Hausenloy, M. R. Duchen, and D. M. Yellon, “Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection,” International Journal of Biochemistry and Cell Biology, vol. 38, no. 3, pp. 414–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Hausenloy, A. Tsang, and D. M. Yellon, “The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning,” Trends in Cardiovascular Medicine, vol. 15, no. 2, pp. 69–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. C. Chen, J. J. Cheng, M. H. Hsieh et al., “Molecular mechanism of the inhibitory effect of trilinolein on endothelin-1-induced hypertrophy of cultured neonatal rat cardiomyocytes,” Planta Medica, vol. 71, no. 6, pp. 525–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Shi, L. Liu, Y. Huo, and Y. Y. Cheng, “Study on protective effects of Panax notoginseng saponins on doxorubicin-induced myocardial damage,” China Journal of Chinese Materia Medica, vol. 32, no. 24, pp. 2632–2635, 2007. View at Google Scholar · View at Scopus
  25. J. Q. Chen, Y. G. Zhang, S. L. Li, Q. Zeng, and M. Z. Rong, “Effects of Panax notoginseng saponins on myocardial adenosinetriphosphatase,” Acta Pharmacologica Sinica, vol. 15, no. 4, pp. 347–350, 1994. View at Google Scholar · View at Scopus
  26. D. M. Cosgrove, F. D. Loop, B. W. Lytle et al., “Predictors of reoperation after myocardial revascularization,” Journal of Thoracic and Cardiovascular Surgery, vol. 92, no. 5, pp. 811–821, 1986. View at Google Scholar · View at Scopus
  27. O. H. Frazier, D. A. Cooley, K. A. Kadipasaoglu et al., “Myocardial revascularization with laser: preliminary findings,” Circulation, vol. 92, no. 9, supplement, pp. II58–II65, 1995. View at Google Scholar · View at Scopus
  28. S. Banai, M. T. Jaklitsch, M. Shou et al., “Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs,” Circulation, vol. 89, no. 5, pp. 2183–2189, 1994. View at Google Scholar · View at Scopus
  29. A. Yanagisawa-Miwa, Y. Uchida, F. Nakamura et al., “Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor,” Science, vol. 257, no. 5075, pp. 1401–1403, 1992. View at Google Scholar · View at Scopus
  30. E. F. Unger, S. Banai, M. Shou et al., “Basic fibroblast growth factor enhances myocardial collateral flow in a canine model,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 266, no. 4, pp. H1588–H1595, 1994. View at Google Scholar · View at Scopus
  31. C. J. Magovern, C. A. Mack, J. Zhang, T. K. Rosengart, O. W. Isom, and R. G. Crystal, “Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor,” Human Gene Therapy, vol. 8, no. 2, pp. 215–227, 1997. View at Google Scholar · View at Scopus
  32. M. Shou, V. Thirumurti, M. A. S. Rajanayagam et al., “Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels,” Journal of the American College of Cardiology, vol. 29, no. 5, pp. 1102–1106, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. R. C. Chiu, A. Zibaitis, and R. L. Kao, “Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation,” Annals of Thoracic Surgery, vol. 60, no. 1, pp. 12–18, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Lei, W. Tian, L. Q. Zhu, J. Yang, and K. J. Chen, “Effects of Radix Ginseng and Radix Notoginseng formula on secretion of vascular endothelial growth factor and expression of vascular endothelial growth factor receptor-2 in human umbilical vein endothelial cells,” Journal of Chinese Integrative Medicine, vol. 8, no. 4, pp. 368–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. World Health Organization and Department of Health Statistics and Informatics in the Information, Evidence and Research Cluster, The Global Burden of Disease 2004 Update, WHO, Geneva, Switzerland, 2004.
  36. P. Davidson, K. Hancock, D. Leung et al., “Traditional Chinese Medicine and heart disease: what does Western medicine and nursing science know about it?” European Journal of Cardiovascular Nursing, vol. 2, no. 3, pp. 171–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Y. Han, H. X. Li, X. Ma et al., “Evaluation of the anti-myocardial ischemia effect of individual and combined extracts of Panax notoginseng and Carthamus tinctorius in rats,” Journal of Ethnopharmacology, vol. 145, no. 3, pp. 722–727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Zhu, L. Wu, C. R. Li et al., “Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis,” Journal of Cellular Biochemistry, vol. 108, no. 1, pp. 117–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Scandinavian Simvastatin Survival Study Group, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Google Scholar · View at Scopus
  40. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. P. S. Sever, B. Dahlöf, N. R. Poulter et al., “Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial,” The Lancet, vol. 361, no. 9364, pp. 1149–1158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels,” The New England Journal of Medicine, vol. 339, no. 19, pp. 1349–1357, 1998. View at Google Scholar
  43. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. A. S. Brown, R. G. Bakker-Arkema, L. Yellen et al., “Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin,” Journal of the American College of Cardiology, vol. 32, no. 3, pp. 665–672, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Xia, C. Sun, Y. Zhao, and L. Wu, “Hypolipidemic and antioxidant activities of Sanchi (Radix Notoginseng) in rats fed with a high fat diet,” Phytomedicine, vol. 18, no. 6, pp. 516–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Rhule, B. Rase, J. R. Smith, and D. M. Shepherd, “Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng,” Journal of Ethnopharmacology, vol. 116, no. 1, pp. 179–186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Wu, W. Zhang, Y. H. Tang et al., “Effect of total saponins of “panax notoginseng root” on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats,” Phytomedicine, vol. 17, no. 3-4, pp. 233–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Wang, L. Wu, W. Zhang, and C. Deng, “Effect of Panax notoginseng saponins on vascular intima hyperplasia and PCNA expression in rat aorta after balloon angioplasty,” China Journal of Chinese Materia Medica, vol. 34, no. 6, pp. 735–739, 2009. View at Google Scholar · View at Scopus
  49. W. Zhang, G. Chen, and C. Q. Deng, “Effects and mechanisms of total Panax notoginseng saponins on proliferation of vascular smooth muscle cells with plasma pharmacology method,” Journal of Pharmacy and Pharmacology, vol. 64, no. 1, pp. 139–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Xu, J. T. Liu, N. Liu, P. P. Lu, and X. M. Pang, “Effects of Panax notoginseng saponins on proliferation and apoptosis of vascular smooth muscle cells,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 226–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. S. G. Lin, X. L. Zheng, Q. Y. Chen, and J. J. Sun, “Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum,” Acta Pharmacologica Sinica, vol. 14, no. 4, pp. 314–316, 1993. View at Google Scholar · View at Scopus
  52. J. Wang and J. H. Hu, “Inhibitory effect of Panax notoginseng on the VSMC proliferation induced by hyperlipidemia serum,” China Journal of Chinese Materia Medica, vol. 31, no. 7, pp. 588–590, 2006. View at Google Scholar · View at Scopus
  53. G. Liu, B. Wang, J. Zhang, H. Jiang, and F. Liu, “Total panax notoginsenosides prevent atherosclerosis in apolipoprotein E-knockout mice: role of downregulation of CD40 and MMP-9 expression,” Journal of Ethnopharmacology, vol. 126, no. 2, pp. 350–354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. H. Qin, L. Q. Zhu, and W. Cui, “Effects of panax notoginseng saponins on expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells injury induced by oxidized low-density lipoprotein,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 12, pp. 1096–1099, 2008. View at Google Scholar · View at Scopus
  55. Y. Liu, H. G. Zhang, Y. Jia, and X. H. Li, “Panax notoginseng saponins attenuate atherogenesis accelerated by zymosan in rabbits,” Biological and Pharmaceutical Bulletin, vol. 33, no. 8, pp. 1324–1330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. S. Fan, D. N. Liu, G. Huang et al., “Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression,” Journal of Ethnopharmacology, vol. 142, no. 3, pp. 732–738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. G. Zhang, H. G. Zhang, G. Y. Zhang et al., “Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 10, pp. 1238–1244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. Z. Yuan, Y. Liao, G. Tian et al., “Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-κB translocation,” Journal of Ethnopharmacology, vol. 138, no. 1, pp. 150–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Wang, J. B. Wan, S. W. Chan et al., “Comparative study on saponin fractions from Panax notoginseng inhibiting inflammation-induced endothelial adhesion molecule expression and monocyte adhesion,” Chinese Medicine, vol. 6, article 37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. S. J. Hong, J. B. Wan, Y. Zhang et al., “Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo,” Phytotherapy Research, vol. 23, no. 5, pp. 677–686, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. S. R. Ommen, J. A. Odell, and M. S. Stanton, “Atrial arrhythmias after cardiothoracic surgery,” The New England Journal of Medicine, vol. 336, no. 20, pp. 1429–1434, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. M. H. Kim, G. M. Deeb, F. Morady et al., “Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (the postoperative atrial fibrillation in cardiac surgery study [PACS2]),” The American Journal of Cardiology, vol. 87, no. 7, pp. 881–885, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Wu, X. M. Zhang, P. M. Liu, J. M. Li, and J. F. Wang, “Effects of Panax notoginseng saponin Rg1 on cardiac electrophysiological properties and ventricular fibrillation threshold in dogs,” Acta Pharmacologica Sinica, vol. 16, no. 5, pp. 459–463, 1995. View at Google Scholar · View at Scopus
  64. D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hypertension: siagnosis, evaluation, and treatment a scientific statement from the American heart association professional education committee of the council for high blood pressure research,” Hypertension, vol. 51, no. 6, pp. 1403–1419, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Y. Kwan and T. K. Kwan, “Effects of Panax notoginseng saponins on vascular endothelial cells in vitro,” Acta Pharmacologica Sinica, vol. 21, no. 12, pp. 1101–1105, 2000. View at Google Scholar · View at Scopus
  66. Y. Y. Guan, J. G. Zhou, Z. Zhang et al., “Ginsenoside-Rd from panax notoginseng blocks Ca2+ influx through receptor- and store-operated Ca2+ channels in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 548, no. 1–3, pp. 129–136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Y. Li, X. G. Wang, M. M. Ma et al., “Ginsenoside-Rd potentiates apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells through the mitochondrial pathway,” Apoptosis, vol. 17, no. 2, pp. 113–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Pan, Y. Huo, X. An et al., “Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation,” Vascular Pharmacology, vol. 56, no. 3-4, pp. 150–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Shemirani, R. Hemmati, A. Khosravi, M. Gharipour, and M. Jozan, “Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction,” Journal of Research in Medical Sciences, vol. 17, no. 2, pp. 133–137, 2012. View at Google Scholar · View at Scopus
  70. T. A. Manolio, D. Levy, R. J. Garrison, W. P. Castelli, and W. B. Kannel, “Relation of alcohol intake to left ventricular mass: the Framingham study,” Journal of the American College of Cardiology, vol. 17, no. 3, pp. 717–721, 1991. View at Google Scholar · View at Scopus
  71. Y. Zhou, L. Tian, and K. Mo, “Relationship between the inhibitory effects of PNS on cardiac hypertrophy and its action on neurohormonal factor,” China Journal of Chinese Materia Medica, vol. 30, no. 12, pp. 916–919, 2005. View at Google Scholar · View at Scopus
  72. P. Feng and H. Jiang, “Effect of total saponins of Panax notoginseng (TSPNS) on myocardial intracellular Ca2+ and activity of calcium pump of membrane of sarcoplasmic reticulum in SHR,” China Journal of Chinese Materia Medica, vol. 23, no. 3, pp. 173–175, 1998. View at Google Scholar · View at Scopus
  73. J. W. Guo, L. M. Li, G. Q. Qiu et al., “Effects of Panax notoginseng saponins on ACE2 and TNF-alpha in rats with post-myocardial infarction-ventricular remodeling,” Journal of Chinese Medicinal Materials, vol. 33, no. 1, pp. 89–92, 2010. View at Google Scholar · View at Scopus
  74. K. Richard, “Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey,” Drug Design, Development and Therapy, vol. 5, pp. 325–380, 2011. View at Publisher · View at Google Scholar
  75. W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics—2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee,” Circulation, vol. 117, no. 4, pp. e25–146, 2008. View at Google Scholar
  76. E. D. Grech, “ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure,” The British Medical Journal, vol. 326, no. 7399, pp. 1137–1140, 2003. View at Google Scholar · View at Scopus
  77. D. Lloyd-Jones, R. J. Adams, T. M. Brown et al., “Executive summary: heart disease and stroke statistics—2010 update: a report from the American heart association,” Circulation, vol. 121, no. 7, pp. 948–954, 2010. View at Publisher · View at Google Scholar
  78. X. J. Xiong, X. C. Yang, Y. M. Liu, Y. Zhang, P. Q. Wang, and J. Wang, “Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science,” Hypertension Research, vol. 36, no. 7, pp. 570–579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. X. J. Xiong, X. C. Yang, W. Liu, F. Y. Chu, P. Q. Wang, and J. Wang, “Trends in the treatment of hypertension from the perspective of traditional chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 275279, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Wang, X. J. Xiong, G. Y. Yang et al., “Chinese herbal medicine Qi Ju di Huang Wan for the treatment of essential hypertension: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 262685, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Wang and X. J. Xiong, “Current situation and perspectives of clinical study in integrative medicine in China,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 268542, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Wang, K. W. Yao, X. C. Yang et al., “Chinese patent medicine Liu Wei di Huang Wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714805, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Aziz, J. L. Morris, and R. A. Perry, “Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation,” Journal of Invasive Cardiology, vol. 19, no. 4, pp. E96–E98, 2007. View at Google Scholar · View at Scopus